Zacks Company Profile for AVEO Pharmaceuticals, Inc. (AVEO : NSDQ) |
|
|
|
Company Description |
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Number of Employees: 115 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $4.02 |
Daily Weekly Monthly
 |
20 Day Moving Average: 232,703 shares |
Shares Outstanding: 34.48 (millions) |
Market Capitalization: $138.60 (millions) |
Beta: 1.17 |
52 Week High: $7.59 |
52 Week Low: $3.06 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-27.44% |
-20.49% |
12 Week |
17.54% |
27.54% |
Year To Date |
-14.29% |
1.93% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Michael Bailey - President; Chief Executive Officer and Director
Erick Lucera - Chief Financial Officer
Kenneth M. Bate - Director
Kevin J. Cullen - Director
Corinne Epperly - Director
|
|
Peer Information
AVEO Pharmaceuticals, Inc. (CORR.)
AVEO Pharmaceuticals, Inc. (RSPI)
AVEO Pharmaceuticals, Inc. (CGXP)
AVEO Pharmaceuticals, Inc. (BGEN)
AVEO Pharmaceuticals, Inc. (GTBP)
AVEO Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 053588307
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
|
|
Share - Related Items
Shares Outstanding: 34.48
Most Recent Split Date: 2.00 (0.10:1)
Beta: 1.17
Market Capitalization: $138.60 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.28 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-1.06 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/04/22 |
|
|
|
|